Comparative analysis of dimethyl fumarate and fingolimod in relapsing-remitting multiple sclerosis.
Johannes LorscheiderPascal BenkertCarmen LienertPeter HänniTobias DerfussJens KuhleLudwig KapposÖzgür YaldizliPublished in: Journal of neurology (2020)
Dimethyl fumarate and fingolimod have comparable effectiveness regarding reduction of relapses and disability worsening in RRMS.